Cyclacel Pharmaceuticals (CYCC) News Today → Biotech's Best Kept Secret: Potential 46,751% Gain (From Behind the Markets) (Ad) Free CYCC Stock Alerts $2.64 +0.62 (+30.69%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 26, 2024 | americanbankingnews.comCyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated by Analysts at StockNews.comMay 14, 2024 | investorplace.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024May 8, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesApril 30, 2024 | msn.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | investorplace.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesApril 29, 2024 | marketwatch.comCyclacel Pharmaceuticals Shares Up 72% After Hours on Withdrawal of OfferingApril 26, 2024 | marketwatch.comCyclacel Pharmaceuticals Shares Hit All-Time Low on Planned Equity SaleApril 25, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near FutureApril 1, 2024 | globenewswire.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerMarch 27, 2024 | money.usnews.comCyclacel Pharmaceuticals IncMarch 21, 2024 | seekingalpha.comCyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call TranscriptMarch 20, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | msn.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023March 19, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 13, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsMarch 7, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 6, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditFebruary 22, 2024 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (CYCCP)February 20, 2024 | globenewswire.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceFebruary 15, 2024 | finance.yahoo.comCyclacel Pharmaceuticals Inc. (UXI.SG)January 8, 2024 | finance.yahoo.comCyclacel Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price RequirementDecember 22, 2023 | msn.comWhy Cyclacel Pharmaceuticals (CYCC) Shares Are Getting ObliteratedDecember 22, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Registered Direct and Private Placement Offering Priced At-The-Market Under Nasdaq RulesDecember 22, 2023 | marketbeat.comTrading was temporarily halted for "CYCC" at 09:12 AM with a stated reason of "LULD pause."December 20, 2023 | msn.comBrookline Capital Downgrades Cyclacel Pharmaceuticals (CYCC)December 18, 2023 | marketbeat.comTrading was temporarily halted for "CYCC" at 07:12 PM with a stated reason of "News pending."December 15, 2023 | benzinga.comCyclacel Pharmaceuticals Stock (NASDAQ:CYCC) Dividends: History, Yield and DatesDecember 12, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Reverse Stock SplitNovember 30, 2023 | msn.comCyclacel Pharmaceuticals regains compliance with Nasdaq listing rulesNovember 28, 2023 | benzinga.comCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNovember 28, 2023 | finance.yahoo.comCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-QNovember 27, 2023 | msn.comCyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94November 24, 2023 | morningstar.comCyclacel Pharmaceuticals Inc CYCCOctober 19, 2023 | msn.comCyclacel Pharmaceuticals, Inc. PFD CONV EX 6% goes ex dividend tomorrowAugust 9, 2023 | msn.comCyclacel Pharmaceuticals GAAP EPS of -$0.44 beats by $0.06, revenue of $0.37MAugust 9, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business UpdateAugust 3, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Release Second Quarter 2023 Financial ResultsJuly 13, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (CYCC) Upgraded to Strong Buy: Here's WhyJune 15, 2023 | forbes.comJointown Pharmaceutical GroupMay 26, 2023 | msn.comOppenheimer Maintains Cyclacel Pharmaceuticals (CYCC) Outperform RecommendationMay 3, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax CreditMarch 8, 2023 | finance.yahoo.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2022 Earnings Call TranscriptMarch 7, 2023 | msn.comOppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To KnowMarch 3, 2023 | msn.comA Preview Of Cyclacel Pharmaceuticals's EarningsJanuary 30, 2023 | finance.yahoo.comCyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor ConferenceDecember 15, 2022 | finance.yahoo.comCyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023November 9, 2022 | seekingalpha.comCyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call TranscriptNovember 8, 2022 | msn.comEarnings Outlook For Cyclacel Pharmaceuticals Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Biotech's Best Kept Secret: Potential 46,751% Gain (Ad)The world's #1 biotech investor has been praising this stock since it was just $18.56. Even though it's rocketed 266% this year, he's now recommending a different biotech entirely! Get the name of the stock here >>> CYCC Media Mentions By Week CYCC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYCC News Sentiment▼0.960.76▲Average Medical News Sentiment CYCC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYCC Articles This Week▼20▲CYCC Articles Average Week Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ZyVersa Therapeutics News Today Ayala Pharmaceuticals News Today Mustang Bio News Today Aptevo Therapeutics News Today 60 Degrees Pharmaceuticals News Today Sonoma Pharmaceuticals News Today Phio Pharmaceuticals News Today Seelos Therapeutics News Today Virios Therapeutics News Today Biodexa Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYCC) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaHow Biden has already won 2024Porter & CompanyThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
